13F Holdings
中文EN

MSLE Satellos Bioscience Inc. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1421642 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-20.5%
TTM EPS YoY21.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-66.4%
ROA-60.2%
ROIC (approx.)-166.7%
Asset turnover—

Leverage & solvency

Liabilities / assets12.9%
Debt / equity0.00x
Current ratio7.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue——
R&D expense$18.43M$14.36M
SG&A expense$8.03M$6.04M
Operating income-$26.46M-$20.40M
Pretax income-$24.70M-$20.63M
Income tax$172,000—
Net income-$24.87M-$20.63M
EPS (basic)-1.70-2.16
EPS (diluted)-1.70-2.16
Weighted avg. shares (diluted)14.60M9.56M
Balance sheet
Cash & equivalents$9.80M$40.07M
Short-term investments$17.91M$8.47M
Current assets$31.88M$50.74M
PP&E, netmay include right-of-use assets (IFRS)$5,000$4,000
Total assets$31.89M$50.75M
Current liabilities$4.11M$3.58M
Total liabilities$4.11M$3.58M
Shareholders' equity$27.78M$47.16M
Cash flow statement
Operating cash flow-$23.60M-$18.25M
Capital expenditure$6,000$4,000
Free cash flow-$23.60M-$18.26M
Investing cash flow-$9.42M$4.66M
Financing cash flow$2.24M$37.57M
Stock-based compensation$3.23M$1.64M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.